As part of a strategy to align with the long-term goals of its pharmaceutical customers, SAS this week said that it has added genomic and proteomic analysis capabilities to its SAS Drug Development software platform, which is primarily targeted to clinical development.

Laurie Rose, director of global health and life science for SAS, said that the integrated system is geared toward researchers who are "breaking down the walls between discovery and development" to bring biomarker and molecular information into their clinical analysis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.